One dog. Same location. Two treatments, 20 days apart.
Thirteen days after the second injection, most of the large tumor mass was gone.
But today, I don’t want to focus on the fact that the tumor disappeared.
I want to talk about something more important:
Being able to treat it again may matter more than clearing everything in one session.
This dog had a malignant tumor at the base of the tongue.
On July 28, we performed the first intratumoral chlorine dioxide ablation.
By Day 5, most of the tumor had disappeared. Because the tumor had already severely destroyed the base of the tongue, the remaining tongue tissue later detached naturally.
But the first treatment did not eliminate everything.
There was still residual tumor.
So 20 days later, on August 17, we treated the same area again.
Before the second injection, there was still a large visible tumor mass.
Thirteen days later, that large mass was essentially gone.
What remained were only about three much smaller suspicious areas, separated from each other and easy to identify individually.
And there was something else that was very important.
There was no large open wound.
No active bleeding.
No obvious inflammatory swelling.
Even the mild bleeding that had persisted after the first treatment was no longer visible.
This is where the real point begins.
Residual tumor is common.
Recurrence is common.
The real limitation of many local cancer treatments is not whether they can technically be repeated.
The real question is:
How many times can you repeat them before the cost to the patient becomes too high?
Many treatments can be done twice.
Some can be done three or four times.
But every treatment may add another layer of tissue damage, organ stress, scarring, structural change, or recovery time.
So the third treatment is often not the same as the first.
That is why I think repeatability may be one of the most important features of intratumoral chlorine dioxide ablation.
It does not rely on heat.
It does not require removing a margin of normal tissue.
The reaction happens quickly inside the treated area.
Bleeding is limited.
Swelling is limited.
Inflammation appears limited.
And the next treatment can remain very similar to the previous one.
In this dog, the two treatments were only 20 days apart.
The second treatment still produced another major reduction in tumor burden.
Once you understand this, the whole treatment strategy changes.
We no longer have to insist that everything must be eliminated in one procedure.
If the cost of repeating treatment is low enough, then complete one-time clearance is no longer the only goal.
If some tumor remains, treat it again.
If another small lesion appears, treat that lesion.
If the tumor grows again later, reduce it again.
The goal becomes keeping the total tumor burden very low for a long period of time.
That is a chronic-disease model of cancer treatment.
We manage hypertension this way.
We manage diabetes this way.
We manage chronic hepatitis this way.
The goal is not always permanent eradication.
The goal is long-term control.
So for a disease that can keep changing, recurring, and growing again, maybe the best treatment is not simply the one that hits hardest once.
Maybe it is the one you can safely and conveniently use again.
And again.
And again.
